368 related articles for article (PubMed ID: 29369782)
1. Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
Shibata A; Uga K; Sato T; Sagara M; Igaki K; Nakamura Y; Ochida A; Kono M; Shirai J; Yamamoto S; Yamasaki M; Tsuchimori N
Biochem Pharmacol; 2018 Apr; 150():35-45. PubMed ID: 29369782
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Evaluation of TAK-828F, a Novel Orally Available RORγt Inverse Agonist, on Murine Colitis Model.
Igaki K; Nakamura Y; Komoike Y; Uga K; Shibata A; Ishimura Y; Yamasaki M; Tsukimi Y; Tsuchimori N
Inflammation; 2019 Feb; 42(1):91-102. PubMed ID: 30121880
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease.
Igaki K; Nakamura Y; Tanaka M; Mizuno S; Yoshimatsu Y; Komoike Y; Uga K; Shibata A; Imaichi H; Takayuki S; Ishimura Y; Yamasaki M; Kanai T; Tsukimi Y; Tsuchimori N
Inflamm Res; 2019 Jun; 68(6):493-509. PubMed ID: 30972425
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological evaluation of TAK-828F, a novel orally available RORγt inverse agonist, on murine chronic experimental autoimmune encephalomyelitis model.
Nakamura Y; Igaki K; Uga K; Shibata A; Yamauchi H; Yamasaki M; Tsuchimori N
J Neuroimmunol; 2019 Oct; 335():577016. PubMed ID: 31374381
[TBL] [Abstract][Full Text] [Related]
5. Biochemical Properties of TAK-828F, a Potent and Selective Retinoid-Related Orphan Receptor Gamma t Inverse Agonist.
Nakagawa H; Koyama R; Kamada Y; Ochida A; Kono M; Shirai J; Yamamoto S; Ambrus-Aikelin G; Sang BC; Nakayama M
Pharmacology; 2018; 102(5-6):244-252. PubMed ID: 30134246
[TBL] [Abstract][Full Text] [Related]
6. Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
Kono M; Ochida A; Oda T; Imada T; Banno Y; Taya N; Masada S; Kawamoto T; Yonemori K; Nara Y; Fukase Y; Yukawa T; Tokuhara H; Skene R; Sang BC; Hoffman ID; Snell GP; Uga K; Shibata A; Igaki K; Nakamura Y; Nakagawa H; Tsuchimori N; Yamasaki M; Shirai J; Yamamoto S
J Med Chem; 2018 Apr; 61(7):2973-2988. PubMed ID: 29510038
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo.
Skepner J; Ramesh R; Trocha M; Schmidt D; Baloglu E; Lobera M; Carlson T; Hill J; Orband-Miller LA; Barnes A; Boudjelal M; Sundrud M; Ghosh S; Yang J
J Immunol; 2014 Mar; 192(6):2564-75. PubMed ID: 24516202
[TBL] [Abstract][Full Text] [Related]
8. Antagonizing Retinoic Acid-Related-Orphan Receptor Gamma Activity Blocks the T Helper 17/Interleukin-17 Pathway Leading to Attenuated Pro-inflammatory Human Keratinocyte and Skin Responses.
Ecoeur F; Weiss J; Kaupmann K; Hintermann S; Orain D; Guntermann C
Front Immunol; 2019; 10():577. PubMed ID: 30972071
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis.
Xue X; Soroosh P; De Leon-Tabaldo A; Luna-Roman R; Sablad M; Rozenkrants N; Yu J; Castro G; Banie H; Fung-Leung WP; Santamaria-Babi L; Schlueter T; Albers M; Leonard K; Budelsky AL; Fourie AM
Sci Rep; 2016 Dec; 6():37977. PubMed ID: 27905482
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo.
Guendisch U; Weiss J; Ecoeur F; Riker JC; Kaupmann K; Kallen J; Hintermann S; Orain D; Dawson J; Billich A; Guntermann C
PLoS One; 2017; 12(11):e0188391. PubMed ID: 29155882
[TBL] [Abstract][Full Text] [Related]
11. Small molecules targeting RORγt inhibit autoimmune disease by suppressing Th17 cell differentiation.
Tan J; Liu H; Huang M; Li N; Tang S; Meng J; Tang S; Zhou H; Kijlstra A; Yang P; Hou S
Cell Death Dis; 2020 Aug; 11(8):697. PubMed ID: 32829384
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.
Xue X; De Leon-Tabaldo A; Luna-Roman R; Castro G; Albers M; Schoetens F; DePrimo S; Devineni D; Wilde T; Goldberg S; Kinzel O; Hoffmann T; Fourie AM; Thurmond RL
Sci Rep; 2021 May; 11(1):11066. PubMed ID: 34040108
[TBL] [Abstract][Full Text] [Related]
13. AT-rich-interactive domain-containing protein 5A functions as a negative regulator of retinoic acid receptor-related orphan nuclear receptor γt-induced Th17 cell differentiation.
Saito Y; Kagami S; Sanayama Y; Ikeda K; Suto A; Kashiwakuma D; Furuta S; Iwamoto I; Nonaka K; Ohara O; Nakajima H
Arthritis Rheumatol; 2014 May; 66(5):1185-94. PubMed ID: 24782182
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and Biological Evaluation of Retinoic Acid-Related Orphan Receptor γt (RORγt) Agonist Structure-Based Functionality Switching Approach from In House RORγt Inverse Agonist to RORγt Agonist.
Yukawa T; Nara Y; Kono M; Sato A; Oda T; Takagi T; Sato T; Banno Y; Taya N; Imada T; Shiokawa Z; Negoro N; Kawamoto T; Koyama R; Uchiyama N; Skene R; Hoffman I; Chen CH; Sang B; Snell G; Katsuyama R; Yamamoto S; Shirai J
J Med Chem; 2019 Feb; 62(3):1167-1179. PubMed ID: 30652849
[TBL] [Abstract][Full Text] [Related]
15. SIRT3 Activator Honokiol Inhibits Th17 Cell Differentiation and Alleviates Colitis.
Chen X; Zhang M; Zhou F; Gu Z; Li Y; Yu T; Peng C; Zhou L; Li X; Zhu D; Zhang X; Yu C
Inflamm Bowel Dis; 2023 Dec; 29(12):1929-1940. PubMed ID: 37335900
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production.
Fujita-Sato S; Ito S; Isobe T; Ohyama T; Wakabayashi K; Morishita K; Ando O; Isono F
J Biol Chem; 2011 Sep; 286(36):31409-17. PubMed ID: 21733845
[TBL] [Abstract][Full Text] [Related]
17. IL-6-mediated Th17 differentiation through RORγt is essential for the initiation of experimental autoimmune myocarditis.
Yamashita T; Iwakura T; Matsui K; Kawaguchi H; Obana M; Hayama A; Maeda M; Izumi Y; Komuro I; Ohsugi Y; Fujimoto M; Naka T; Kishimoto T; Nakayama H; Fujio Y
Cardiovasc Res; 2011 Sep; 91(4):640-8. PubMed ID: 21622681
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel quinazolinedione derivatives as RORγt inverse agonist.
Fukase Y; Sato A; Tomata Y; Ochida A; Kono M; Yonemori K; Koga K; Okui T; Yamasaki M; Fujitani Y; Nakagawa H; Koyama R; Nakayama M; Skene R; Sang BC; Hoffman I; Shirai J; Yamamoto S
Bioorg Med Chem; 2018 Feb; 26(3):721-736. PubMed ID: 29342416
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells.
Sujino T; Kanai T; Ono Y; Mikami Y; Hayashi A; Doi T; Matsuoka K; Hisamatsu T; Takaishi H; Ogata H; Yoshimura A; Littman DR; Hibi T
Gastroenterology; 2011 Sep; 141(3):1014-23. PubMed ID: 21699791
[TBL] [Abstract][Full Text] [Related]
20. Neomangiferin modulates the Th17/Treg balance and ameliorates colitis in mice.
Lim SM; Kang GD; Jeong JJ; Choi HS; Kim DH
Phytomedicine; 2016 Feb; 23(2):131-40. PubMed ID: 26926174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
